Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Contineum Therapeutics (CTNM) Assets Average (2024 - 2026)

Contineum Therapeutics' Assets Average history spans 3 years, with the latest figure at $269.0 million for Q1 2026.

  • Quarterly Assets Average rose 30.86% to $269.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $269.0 million through Mar 2026, up 30.86% year-over-year, with the annual reading at $244.7 million for FY2025, 42.61% up from the prior year.
  • Assets Average came in at $269.0 million for Q1 2026, up from $233.7 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $269.0 million in Q1 2026 to a low of $127.0 million in Q1 2024.
  • The 3-year median for Assets Average is $205.6 million (2025), against an average of $202.0 million.
  • The largest YoY upside for Assets Average was 61.89% in 2025 against a maximum downside of 14.55% in 2025.
  • Contineum Therapeutics' Assets Average stood at $214.4 million in 2024, then rose by 9.0% to $233.7 million in 2025, then rose by 15.08% to $269.0 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Assets Average are $269.0 million (Q1 2026), $233.7 million (Q4 2025), and $186.9 million (Q3 2025).